短链脂肪酸对老年2型糖尿病合并肌少症的影响及其机制

doi:10.3969/j.issn.1003-9198.2025.01.022

Abstract

Abstract: Sarcopenia is the main factor leading to disability and decreased quality of life in the elderly patients with type 2 diabetes mellitus. Many studies show that short-chain fatty acids (SCFAs) are involved in the regulation of intracellular signal transduction and insulin sensitivity, inflammatory factors, protein metabolism and fatty acid oxidation in muscle cells, and have a protective effect in the elderly patients with type 2 diabetes mellitus complicated with sarcopenia. This article reviews the above contents in order to provide a new method for clinical intervention of type 2 diabetes mellitus combined with sarcopenia in the elderly.

Key words: aged, type 2 diabetes mellitus, sarcopenia, enteric microorganism, short-chain fatty acids, mechanism

CLC Number:

SONG Chengya, YANG Ying, HONG Kan. Effect and mechanism of short-chain fatty acids on sarcopenia in elderly patients complicated with type 2 diabetes mellitus[J]. Practical Geriatrics, 2025, 39(1): 98-101.

References

[1] LI Y, TENG D, SHI X, et al.Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American diabetes association: national cross sectional study[J]. BMJ, 2020, 369: m997.
[2] ZHANG S, QI Z, WANG Y, et al. Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis[J]. Front Endocrinol, 2023, 14: 1203666.
[3] ARGYROPOULOU D, GELADAS N D, NOMIKOS T, et al. Exercise and nutrition strategies for combating sarcopenia and type 2 diabetes mellitus in older adults[J]. J Funct Morphol Kinesiol, 2022, 7(2): 48.
[4] STRASSER B, WOLTERS M, WEYH C, et al. The effects of lifestyle and diet on gut microbiota composition, inflammation and muscle performance in our aging society[J]. Nutrients, 2021, 13(6): 2045.
[5] PURNAMASARI D, TETRASIWI E N, KARTIKO G J, et al.Sarcopenia and chronic complications of type 2 diabetes mellitus[J]. Rev Diabet Stud, 2022, 18(3): 157-165.
[6] TRIERWEILER H, KISIELEWICZ G, HOFFMANN JONASSON T, et al. Sarcopenia: a chronic complication of type 2 diabetes mellitus[J]. Diabetol Metab Syndr, 2018, 10: 25.
[7] FENG L, GAO Q, HU K, et al. Prevalence and risk factors of sarcopenia in patients with diabetes: a meta-analysis[J]. J Clin Endocrinol Metab, 2022, 107(5): 1470-1483.
[8] WENDOWSKI O, REDSHAW Z, MUTUNGI G. Dihydrotestosterone treatment rescues the decline in protein synthesis as a result of sarcopenia in isolated mouse skeletal muscle fibres[J]. J Cachexia Sarcopenia Muscle, 2017, 8(1): 48-56.
[9] OBERBACH A, BOSSENZ Y, LEHMANN S, et al. Altered fiber distribution and fiber-specific glycolytic and oxidative enzyme activity in skeletal muscle of patients with type 2 diabetes[J]. Diabetes Care, 2006, 29(4): 895-900.
[10] ALBERS P H, PEDERSEN A J T, BIRK J B, et al. Human muscle fiber type-specific insulin signaling: impact of obesity and type 2 diabetes[J]. Diabetes, 2015, 64(2): 485-497.
[11] CAO Y, LI Y, HAN W, et al.Sodium butyrate ameliorates type 2 diabetes-related sarcopenia through IL-33-independent ILC2s/IL-13/STAT3 signaling pathway[J]. J Inflamm Res, 2023, 16: 343-358.
[12] LIU Z, GUO Y, ZHENG C. Type 2 diabetes mellitus related sarcopenia: a type of muscle loss distinct from sarcopenia and disuse muscle atrophy[J]. Front Endocrinol, 2024, 15: 1375610.
[13] MARTIN-GALLAUSIAUX C, MARINELLI L, BLOTTIÈRE H M, et al. SCFA: mechanisms and functional importance in the gut[J]. Proc Nutr Soc, 2021, 80(1): 37-49.
[14] KOH A, DE VADDER F, KOVATCHEVA-DATCHARY P, et al. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites[J]. Cell, 2016, 165(6): 1332-1345.
[15] CRUDELE L, GADALETA R M, CARIELLO M, et al. Gut microbiota in the pathogenesis and therapeutic approaches of diabetes[J]. EBioMedicine, 2023, 97: 104821.
[16] TICINESI A, MANCABELLI L, TAGLIAFERRI S, et al. The gut-muscle axis in older subjects with low muscle mass and performance: a proof of concept study exploring fecal microbiota composition and function with shotgun metagenomics sequencing[J]. Int J Mol Sci, 2020, 21(23): 8946.
[17] LAU W L, VAZIRI N D. Gut microbial short-chain fatty acids and the risk of diabetes[J]. Nat Rev Nephrol, 2019, 15(7): 389-390.
[18] OTSUKA R, ZHANG S, FURUYA K, et al. Association between short-chain fatty acid intake and development of muscle strength loss among community-dwelling older Japanese adults[J]. Exp Gerontol, 2023, 173: 112080.
[19] LV W Q, LIN X, SHEN H, et al. Human gut microbiome impacts skeletal muscle mass via gut microbial synthesis of the short-chain fatty acid butyrate among healthy menopausal women[J]. Cachexia Sarcopenia Muscle, 2021, 12(6): 1860-1870.
[20] VAN DER HEE B, WELLS J M. Microbial regulation of host physiology by short-chain fatty acids[J]. Trends Microbiol, 2021, 29(8): 700-712.
[21] CHAMBERS E S, PRESTON T, FROST G, et al. Role of gut microbiota-generated short-chain fatty acids in metabolic and cardiovascular health[J]. Curr Nutr Rep, 2018, 7(4): 198-206.
[22] MARUTA H, YAMASHITA H. Acetic acid stimulates G-protein-coupled receptor GPR43 and induces intracellular calcium influx in L6 myotube cells[J]. PLoS One, 2020, 15(9): e0239428.
[23] HU J, LIN S, ZHENG B, et al. Short-chain fatty acids in control of energy metabolism[J]. Crit Rev Food Sci Nutr, 2018, 58(8): 1243-1249.
[24] HASHIMOTO Y, TAKAHASHI F, OKAMURA T, et al. Diet, exercise, and pharmacotherapy for sarcopenia in people with diabetes[J]. Metabolism, 2023, 144: 155585.
[25] FRAMPTON J, MURPHY K G, FROST G, et al. Short-chain fatty acids as potential regulators of skeletal muscle metabolism and function[J]. Nat Metab, 2020, 2(9): 840-848.
[26] JIANG Y, LI K, LI X, et al.Sodium butyrate ameliorates the impairment of synaptic plasticity by inhibiting the neuroinflammation in 5XFAD mice[J]. Chem Biol Interact, 2021, 341: 109452.
[27] GAO Z, YIN J, ZHANG J, et al.Butyrate improves insulin sensitivity and increases energy expenditure in mice[J]. Diabetes, 2009, 58(7): 1509-1517.
[28] WALSH M E, VAN REMMEN H. Emerging roles for histone deacetylases in age-related muscle atrophy[J]. Nutr Healthy Aging, 2016, 4(1): 17-30.
[29] ZHANG X, LI H, HE M, et al. Immune system and sarcopenia: presented relationship and future perspective[J]. Exp Gerontol, 2022, 164: 111823.
[30] CHEN H, HUANG X, DONG M, et al. The association between sarcopenia and diabetes: from pathophysiology mechanism to therapeutic strategy[J]. Diabetes Metab Syndr Obes, 2023, 16: 1541-1554.
[31] ZHONG H, YU H, CHEN J, et al.The short-chain fatty acid butyrate accelerates vascular calcification via regulation of histone deacetylases and NF-κB signaling[J]. Vascul Pharmacol, 2022, 146: 107096.
[32] FAN Z, WU J, CHEN Q N, et al. Type 2 diabetes-induced overactivation of P300 contributes to skeletal muscle atrophy by inhibiting autophagic flux[J]. Life Sci, 2020, 258: 118243.
[33] KALKAN H, PAGANO E, PARIS D, et al. Targeting gut dysbiosis against inflammation and impaired autophagy in Duchenne muscular dystrophy[J]. EMBO Mol Med, 2023, 15(3): e16225.
[34] CHRIETT S. CA-006: Le butyrate et le βHydroxybutyrate diminuent l’insulino-résistance des myotubes induite par les acides gras à longue chaine par des mécanismes différents[J]. Diabetes Metab, 2016, 42(suppl 1): A36.
[35] BESIO R, IULA G, GARIBALDI N, et al. 4-PBA ameliorates cellular homeostasis in fibroblasts from osteogenesis imperfecta patients by enhancing autophagy and stimulating protein secretion[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(5 Pt A): 1642-1652.
[36] TICINESI A, NOUVENNE A, CERUNDOLO N, et al. Gut microbiota, muscle mass and function in aging: a focus on physical frailty and sarcopenia[J]. Nutrients, 2019, 11(7): 1633.
[37] KAHN S E, HULL R L, UTZSCHNEIDER K M. Mechanisms linking obesity to insulin resistance and type 2 diabetes[J]. Nature, 2006, 444(7121): 840-846.
[38] BITTEL D C, BITTEL A J, TUTTLE L J, et al. Adipose tissue content, muscle performance and physical function in obese adults with type 2 diabetes mellitus and peripheral neuropathy[J]. J Diabetes Complications, 2015, 29(2): 250-257.
[39] MEEX R C R, BLAAK E E, VAN LOON L J C. Lipotoxicity plays a key role in the development of both insulin resistance and muscle atrophy in patients with type 2 diabetes[J]. Obes Rev, 2019, 20(9): 1205-1217.
[40] LIU C, CHEUNG W H, LI J, et al.Understanding the gut microbiota and sarcopenia: a systematic review[J]. J Cachexia Sarcopenia Muscle, 2021, 12(6): 1393-1407.
[41] SALES K M, REIMER R A.Unlocking a novel determinant of athletic performance: the role of the gut microbiota, short-chain fatty acids, and “biotics” in exercise[J]. J Sport Health Sci, 2023, 12(1): 36-44.
[42] 何方,李金星,吴思谋. 肠源性短链脂肪酸生成机制及其饮食调控[J]. 食品科学技术学报,2023,41(1):10-21.
[43] LAHIRI S, KIM H, GARCIA-PEREZ I, et al. The gut microbiota influences skeletal muscle mass and function in mice[J]. Sci Transl Med, 2019, 11(502): eaan5662.

Effect and mechanism of short-chain fatty acids on sarcopenia in elderly patients complicated with type 2 diabetes mellitus

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Recommended 0

[1]	DONG Xiaofei, ZHANG Fei, WANG Jiahe. Relationship between environmental exposure and sarcopenia [J]. Practical Geriatrics, 2025, 39(1): 8-11.
[2]	YANG Na, HU Zhongyi, GAO Yang. Effects of environmental exposure on geriatric depression [J]. Practical Geriatrics, 2025, 39(1): 12-16.
[3]	WANG Xue, ZHANG Zhenyong, XU Bin, ZHU Ya, ZHOU Xuan, ZHANG Yongjia, ZHUANG Ruijuan. Study on association of serum levels of VEGF and BDNF with severity of vascular dementia and predictive value for prognosis [J]. Practical Geriatrics, 2025, 39(1): 32-36.
[4]	LIU Chuan, PAN Yiming, YU Wenhua, ZHANG Wanshu, LI Jiatong, LI Xiaxia, XING Yiwen, LI Jing, MA Lina. Reliability and validity of the Clinical pHysical rEsilience assEssment Scale (CHEES) in elderly inpatients [J]. Practical Geriatrics, 2025, 39(1): 37-40.
[5]	ZHOU Jing, SUN Luoyang, WANG Ling, MA Jiaxu. Effects of erector spinae plane block combined with stellate ganglion block in elderly patients undergoing total laparoscopic hysterectomy [J]. Practical Geriatrics, 2025, 39(1): 51-55.
[6]	WANG Meijuan, JIANG Xuezhong, WANG Hui, LIU Xiaojing, PANG Huiyan. Application value of two-dimensional speckle tracking imaging in assessing arterial function in overweight elderly with normal carotid artery structure [J]. Practical Geriatrics, 2025, 39(1): 56-60.
[7]	YIN Pengcheng, WANG Xinzhi, ZHANG Linzhong. Study on nonlinear analysis of EEG related to memory ability in elderly patients [J]. Practical Geriatrics, 2025, 39(1): 61-65.
[8]	ZHANG Siqi, SUN Xiaoxing, YANG Shili, GE Hongfeng, FENG Jiangzhou. Analysis of the efficacy and factors affecting the second-line treatment of chronic myeloid leukemia in the elderly receiving flumatinib [J]. Practical Geriatrics, 2025, 39(1): 70-73.
[9]	LI Ting, PEI Junfang, SUN Shanshan. Drug resistance of pathogenic bacteria and effects of drug resistance degree on serum levels of IL-6, IL-10 and CRP in elderly patients with pulmonary infection [J]. Practical Geriatrics, 2025, 39(1): 83-87.
[10]	WU Wangyi, ZHAO Chunyan, SUN Yuxiao. Effects of different dietary structures on postprandial hypotension after breakfast in elderly patients with hypertension [J]. Practical Geriatrics, 2025, 39(1): 88-92.
[11]	ZHAO Shuqing, ZHAO Ying, ZHANG Yu, LU Xiaohui. A review of cellular senescence in chronic heart failure [J]. Practical Geriatrics, 2025, 39(1): 93-97.
[12]	LI Jiang, QIU Yan, WANG Ting, WANG Dan, YU Yifan, PU Lingli, BU Ling. Correlation between preoperative SII/ALB and clinicopathologic features in elderly patients with lung adenocarcinoma [J]. Practical Geriatrics, 2024, 38(9): 893-896.
[13]	QI Jiaying, YIN Tongtong, WANG Fangfang, ZHANG Hui, WANG Li. A dose-response Meta-analysis of the association between physical activity and the risk of sarcopenia in the elderly [J]. Practical Geriatrics, 2024, 38(9): 905-910.
[14]	GAO Yuan, CHEN Hua, CHEN Ke, HUANG Wenlong. Relationship of bone mineral density and fracture risk with type 2 diabetes mellitus-related factors in elderly patients [J]. Practical Geriatrics, 2024, 38(9): 911-915.
[15]	DAI Jing, CUI Yan. Correlation between glycosylated hemoglobin variability and cognitive dysfunction in elderly patients with type 2 diabetes mellitus [J]. Practical Geriatrics, 2024, 38(9): 931-935.